Should PARP Inhibitors Have Tumor-Agnostic Approval Status? Should PARP Inhibitors Have Tumor-Agnostic Approval Status?

We have strong data for the benefits of PARP inhibitors in metastatic cancers in the presence of germline BRCA mutations, but is it enough to drive their tumor-agnostic approval?Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news